Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis

Aim. To systematize data on the prevalence and risk of small intestinal bacterial overgrowth (SIBO) in patients with rosacea. Materials and methods. The search for studies was conducted in the MEDLINE/PubMed, EMBASE, and the Russian Science Citation Index from January 1, 1985, to April 5, 2025. T...

Full description

Saved in:
Bibliographic Details
Main Authors: А. R. Khurmatullina, Yu. A. Kucheryavyy, D. N. Andreev, O. B. Tamrazova, I. V. Maev
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2025-01-01
Series:Терапевтический архив
Subjects:
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/678886/203851
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850043667958464512
author А. R. Khurmatullina
Yu. A. Kucheryavyy
D. N. Andreev
O. B. Tamrazova
I. V. Maev
author_facet А. R. Khurmatullina
Yu. A. Kucheryavyy
D. N. Andreev
O. B. Tamrazova
I. V. Maev
author_sort А. R. Khurmatullina
collection DOAJ
description Aim. To systematize data on the prevalence and risk of small intestinal bacterial overgrowth (SIBO) in patients with rosacea. Materials and methods. The search for studies was conducted in the MEDLINE/PubMed, EMBASE, and the Russian Science Citation Index from January 1, 1985, to April 5, 2025. The inclusion criteria were original clinical studies in English or Russian with detailed descriptive statistics describing the prevalence of SIBO in adults with rosacea. The analysis included an assessment of the SIBO prevalence, calculation of relative risk, and 95% confidence interval (CI) using a random effects model. Heterogeneity was assessed using I²-statistics, and publication bias was examined with funnel plots and Begg–Mazumdar and Egger tests. Results. The meta-analysis included 6 studies with 801 subjects (581 subjects with rosacea, 220 controls). The overall prevalence of SIBO in patients with rosacea was 35.8% (95% CI 23.626–48.985) compared to 9.391% (95% CI 4.256–16.265) in controls. The risk of developing SIBO in patients with rosacea was 3.501 times higher (relative risk 3.50; 95% CI 1.347–9.100; p=0.012). Treatment with rifaximin (1200 mg/day for 10 days) resulted in significant improvement or remission of rosacea in 57.9% (95% CI 49.5–66.3) of patients, with the highest effectiveness (up to 85.7%) observed in those with successful eradication of SIBO. Conclusion. The results of a systematic review and meta-analysis confirm the potential association between SIBO and rosacea and demonstrate the effectiveness of rifaximin in treating cutaneous manifestations of rosacea in these patients. It is necessary to consider SIBO diagnosis when assessing patients with rosacea, especially in resistant forms of the disease.
format Article
id doaj-art-e060ec1d805b4466bfbadd0995ab56eb
institution DOAJ
issn 0040-3660
2309-5342
language Russian
publishDate 2025-01-01
publisher "Consilium Medicum" Publishing house
record_format Article
series Терапевтический архив
spelling doaj-art-e060ec1d805b4466bfbadd0995ab56eb2025-08-20T02:55:10Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422025-01-0197758058610.26442/00403660.2025.07.20329778724Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysisА. R. Khurmatullina0https://orcid.org/0009-0000-4358-7823Yu. A. Kucheryavyy1https://orcid.org/0000-0001-7760-2091D. N. Andreev2https://orcid.org/0000-0002-4007-7112O. B. Tamrazova3https://orcid.org/0000-0003-3261-6718I. V. Maev4https://orcid.org/0000-0001-6114-564XSechenov First Moscow State Medical University (Sechenov University)Ilyinskaya Hospital JSCRussian University of MedicinePeoples' Friendship University of Russia named after Patrice LumumbaRussian University of MedicineAim. To systematize data on the prevalence and risk of small intestinal bacterial overgrowth (SIBO) in patients with rosacea. Materials and methods. The search for studies was conducted in the MEDLINE/PubMed, EMBASE, and the Russian Science Citation Index from January 1, 1985, to April 5, 2025. The inclusion criteria were original clinical studies in English or Russian with detailed descriptive statistics describing the prevalence of SIBO in adults with rosacea. The analysis included an assessment of the SIBO prevalence, calculation of relative risk, and 95% confidence interval (CI) using a random effects model. Heterogeneity was assessed using I²-statistics, and publication bias was examined with funnel plots and Begg–Mazumdar and Egger tests. Results. The meta-analysis included 6 studies with 801 subjects (581 subjects with rosacea, 220 controls). The overall prevalence of SIBO in patients with rosacea was 35.8% (95% CI 23.626–48.985) compared to 9.391% (95% CI 4.256–16.265) in controls. The risk of developing SIBO in patients with rosacea was 3.501 times higher (relative risk 3.50; 95% CI 1.347–9.100; p=0.012). Treatment with rifaximin (1200 mg/day for 10 days) resulted in significant improvement or remission of rosacea in 57.9% (95% CI 49.5–66.3) of patients, with the highest effectiveness (up to 85.7%) observed in those with successful eradication of SIBO. Conclusion. The results of a systematic review and meta-analysis confirm the potential association between SIBO and rosacea and demonstrate the effectiveness of rifaximin in treating cutaneous manifestations of rosacea in these patients. It is necessary to consider SIBO diagnosis when assessing patients with rosacea, especially in resistant forms of the disease.https://ter-arkhiv.ru/0040-3660/article/viewFile/678886/203851bacterial overgrowth syndromerosacearifaximinmeta-analysis
spellingShingle А. R. Khurmatullina
Yu. A. Kucheryavyy
D. N. Andreev
O. B. Tamrazova
I. V. Maev
Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis
Терапевтический архив
bacterial overgrowth syndrome
rosacea
rifaximin
meta-analysis
title Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis
title_full Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis
title_fullStr Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis
title_full_unstemmed Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis
title_short Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis
title_sort prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea a systematic review and meta analysis
topic bacterial overgrowth syndrome
rosacea
rifaximin
meta-analysis
url https://ter-arkhiv.ru/0040-3660/article/viewFile/678886/203851
work_keys_str_mv AT arkhurmatullina prevalenceandriskofsmallintestinalbacterialovergrowthinpatientswithrosaceaasystematicreviewandmetaanalysis
AT yuakucheryavyy prevalenceandriskofsmallintestinalbacterialovergrowthinpatientswithrosaceaasystematicreviewandmetaanalysis
AT dnandreev prevalenceandriskofsmallintestinalbacterialovergrowthinpatientswithrosaceaasystematicreviewandmetaanalysis
AT obtamrazova prevalenceandriskofsmallintestinalbacterialovergrowthinpatientswithrosaceaasystematicreviewandmetaanalysis
AT ivmaev prevalenceandriskofsmallintestinalbacterialovergrowthinpatientswithrosaceaasystematicreviewandmetaanalysis